Eppendorf with broad-based growth above market average

The Eppendorf Group continued to perform well in the first half year 2018. Group sales increased from EUR 327.9 million to EUR 335.6 million compared to the same period of the previous year, corresponding to a growth of 2.4 percent. Exchange rate adjusted, Eppendorf achieved a sales growth of 8.6 percent. The operating result (EBIT) increased by 6.4 percent to EUR 67.3 million (previous year: 63.2 million). This corresponds to an EBIT margin of 20.0 percent (previous year: 19.3 percent). All Eppendorf market regions and product groups contributed to the positive overall result. Thomas Bachmann, Chief Executive Officer of Eppendorf AG, comments: "We are pleased that Eppendorf again successfully asserted itself in the first half of 2018 and gained market shares in important regions. The initiatives promoted in 2017, with a focus on going-to-market, innovation and infrastructure for the further development of our company, have proven to be effective. Thanks to a new global sales strategy and innovations in marketing, we serve our markets in a much more targeted manner, but also increasingly geared towards the purchasing habits of a younger generation of customers. Our intensified innovation activity is reflected in a considerable number of new products that we successfully launched on the market during the reporting period."

Outlook

With this favorable situation at the middle of the year, Eppendorf is confident that it will achieve growth well above the market average and further progress in the company's sustainable development for the entire 2018 financial year. Source: Eppendorf AG Press Release from August 3rd, 2018, https://corporate.eppendorf.com/en/news-media/press-releases/

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …